• Skip to main content
  • Skip to footer
  • 240.243.1201
  • info@glycomimetics.com
  • Careers
  • Contact Us
Glycomimetics
  • About Us
    • Management Team
    • Board of Directors
    • Core Values
  • Patients
    • Clinical Trials
    • Expanded Access
  • Pipeline
    • Programs
      • Uproleselan/GMI-1687
      • GMI-1359
      • Galectin Antagonists
      • Rivipansel (GMI-1070)
    • Therapeutic Focus
      • Acute Myeloid Leukemia (AML)
      • Sickle Cell Disease
  • Technology & Publications
    • Scientific Publications
    • Intellectual Property
    • Platform & Research
  • Collaborations
  • Investors
    • Press Releases
    • Corporate Presentation
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
      • Ownership Profile
  • Careers
  • Contact Us
  • Search

GlycoMimetics is evaluating its drug candidate
uproleselan (GMI-1271)
in adults with acute myeloid leukemia.

Our pivotal trial for uproleselan is being conducted under the auspices of the FDA’s Breakthrough Therapy designation.

We believe targeting tumors with GMI-1359, a compound that inhibits both E-selectin and CXCR4, could improve efficacy in the treatment of cancers that have a propensity to metastasize to bone.

We are applying our expertise in carbohydrate biology and chemistry to design high-potency
antagonists of galectin-3.

These therapies could be instrumental in treating fibrosis and various forms of cancer

Our expertise in glycosciences distinguishes our development of potentially groundbreaking therapies to treat serious oncology, immunology, and inflammatory conditions.

News

January 7, 2021
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia

December 7, 2020
New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition

December 5, 2020
GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model

Events

There are currently no upcoming events.

Partnering

Collaborations are vital to the success of our business.

To drive our proprietary programs forward, we have developed significant alliances with leading academics, governmental organizations and pharmaceutical/ biotechnology companies.

Learn More

Footer

Questions?

Contact GlycoMimetics Today

Get in Touch

© GlycoMimetics All rights reserved. Website Design & Development: Graphic Beans

Site Map | Terms of Use | Privacy | Contact Us